Home › Funds › Amova Asset Management Americas, Inc. › NTLA
Amova Asset Management Americas, Inc. position in NTLA
INTELLIA THERAPEUTICS INC · Health Care
Amova Asset Management Americas, Inc. reported holding 3,610,687 shares of NTLA (INTELLIA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$43.5M, representing 0.54% of its reported portfolio and ranking #46 among its reported holdings. Amova Asset Management Americas, Inc. has disclosed NTLA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Amova Asset Management Americas, Inc.'s NTLA position evolved
Amova Asset Management Americas, Inc. first disclosed a stake in NTLA in Q3 2023 at 3,520,295 shares (US$111.2M). Across 13 filings, Amova Asset Management Americas, Inc. increased the stake 2 time(s), trimmed it 10 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 3,610,687 shares valued at US$43.5M — an increase of 713,158 shares quarter over quarter.. Notable position changes include a 47% increase in Q2 2026 (shares fell 29% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.52M | $111.17M | New |
| Q4 2023 | 3.48M | $105.96M | Reduce |
| Q1 2024 | 3.40M | $93.38M | Reduce |
| Q2 2024 | 3.26M | $72.91M | Reduce |
| Q3 2024 | 3.15M | $64.67M | Reduce |
| Q4 2024 | 2.99M | $34.89M | Reduce |
| Q1 2025 | 2.83M | $20.00M | Reduce |
| Q2 2025 | 2.67M | $25.00M | Reduce |
| Q3 2025 | 2.35M | $40.62M | Reduce |
| Q4 2025 | 2.19M | $19.69M | Reduce |
| Q1 2026 | 1.97M | $25.27M | Reduce |
| Q2 2026 | 2.90M | $49.03M | Add |
| Q3 2026 | 3.61M | $43.51M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NTLA and 13F data
NTLA (INTELLIA THERAPEUTICS INC) is a Health Care company. 33 other funds we track also report a position in NTLA — the largest reported positions include ARK Invest (US$192.1M), RA CAPITAL MANAGEMENT, L.P. (US$76.6M), REGENERON PHARMACEUTICALS, INC. (US$44.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NTLA
- ARK Invest 15.93M sh · $192.06M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 4.53M sh · $76.60M · Q2 2026
- REGENERON PHARMACEUTICALS, INC. 3.70M sh · $44.66M · Q3 2026
- Contrarius Group Holdings Ltd 2.43M sh · $29.33M · Q3 2026
- ARMISTICE CAPITAL, LLC 1.50M sh · $25.38M · Q2 2026
- Ghisallo Capital Management LLC 1.20M sh · $20.30M · Q2 2026
More on Amova Asset Management Americas, Inc.
FAQ
How long has Amova Asset Management Americas, Inc. held NTLA?
Amova Asset Management Americas, Inc. has disclosed NTLA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Amova Asset Management Americas, Inc.'s current position in NTLA?
As of Q3 2026, Amova Asset Management Americas, Inc. holds 3.61M shares of NTLA (INTELLIA THERAPEUTICS INC), valued at $43.51M, representing 0.54% of its reported portfolio and ranking #46.
Has Amova Asset Management Americas, Inc. been buying or selling NTLA?
In the latest 13F filing (Q3 2026), Amova Asset Management Americas, Inc. increased its position in NTLA.
Which other funds hold NTLA?
Other major institutional holders of NTLA include ARK Invest, RA CAPITAL MANAGEMENT, L.P., REGENERON PHARMACEUTICALS, INC., among 33 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.